Therapeutic strategies to overcome EGFR mutations as acquired resistance mechanism in ALK-rearranged non-small-cell lung cancer: Case Reports

INTRODUCTION: ALK tyrosine kinase inhibitors (ALK TKIs) have improved prognosis in ALK-rearranged (ALK (+)) non-small-cell lung cancer (NSCLC). However, drug resistance mechanisms occur inevitably during the course of treatment leading to disease progression. Activation of epidermal growth factor re...

Descripción completa

Detalles Bibliográficos
Autores principales: Michaux, Lionel, Perrier, Alexandre, Mehlman, Camille, Alshehhi, Hussa, Dubois, Antonin, Lacave, Roger, Coulet, Florence, Cadranel, Jacques, Fallet, Vincent
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10338053/
https://www.ncbi.nlm.nih.gov/pubmed/37448514
http://dx.doi.org/10.3389/fonc.2023.1182558

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10338053/
https://www.ncbi.nlm.nih.gov/pubmed/37448514
http://dx.doi.org/10.3389/fonc.2023.1182558

Ejemplares similares